Gamma-oryzanol alleviates osteoarthritis development by targeting Keap1–Nrf2 binding to interfere with chondrocyte ferroptosis
International Immunopharmacology · 2024-02 · 128 · 111469
DOI: 10.1016/j.intimp.2023.111469 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-02. Verfasst von Zi-Han Dai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, The First Affiliated Hospital of Wenzhou Medical University, 2# Fuxue Lane, Wenzhou 325000, Zhejiang Province, China; The S…. Hauptthemen laut MEDLINE: Ferroptosis, Osteoarthritis, Phenylpropionates. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Wenzhou Medical University.
Abstract (Originalsprache)
Osteoarthritis (OA) is a prevalent joint disorder pathologically correlated to chondrocyte ferroptosis. Gamma-oryzanol (γ-Ory), as a first-line drug for autonomic disorders, aroused our interest because of its antioxidant, lipid-lowering, and hypoglycemic potential. The purpose of this study was to investigate the potential impact and mechanism of γ-Ory in treating OA. And the inhibition of γ-Ory in extracellular matrix molecule (ECM) degradation, ferroptosis, and Keap1-Nrf2 binding in IL-1β-exposed chondrocytes was detected via immunoblotting, immunofluorescence, and co-immunoprecipitation. Micro-CT, SO staining, and immunofluorescence have been conducted to assess the impact of γ-Ory treatment on ACLT-mediated OA in rats at both imaging and histological stages. We found that γ-Ory dose-dependently suppressed IL-1β-induced ECM deterioration and chondrocyte ferroptosis. Our animal experiments revealed that γ-Ory delayed ACLT-mediated OA development. Mechanistically, γ-Ory interfered with the binding of Keap1 to Nrf2 to promote the latter's nuclear import, thereby increasing the expression of detoxification enzymes. Summarily, our works support γ-Ory's potential as a candidate drug for the treatment of OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, The First Affiliated Hospital of Wenzhou Medical University, 2# Fuxue Lane, Wenzhou 325000, Zhejiang Province, China; The Second School of Medicine, Wenzhou Medical University, Wenzhou 325000,…
- The Second School of Medicine, Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China.
- Key Laboratory of Orthopaedics of Zhejiang Province, Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109# Xueyuan Road, Wenzhou 325000, Zhejiang P…
- Department of Ultrasound, The First Affiliated Hospital of Wenzhou Medical University, 2# Fuxue Lane, Wenzhou 325000, Zhejiang Province, China. Electronic address: 363622295@qq.com.
Förderung
- Natural Science Foundation of Zhejiang Province
- Wenzhou Medical University
Zitieren
APA
Dai, Z. H., Zhou, C. C., Yu, C. Y., Qian, C. J., Jin, S. Q., Du, S. Q., Lv, Y. Y., Jin, C., Zheng, G., & Zhan, Y. (2024). Gamma-oryzanol alleviates osteoarthritis development by targeting Keap1–Nrf2 binding to interfere with chondrocyte ferroptosis. International Immunopharmacology, 128, 111469. https://doi.org/10.1016/j.intimp.2023.111469
Vancouver
Dai ZH, Zhou CC, Yu CY, Qian CJ, Jin SQ, Du SQ, et al. Gamma-oryzanol alleviates osteoarthritis development by targeting Keap1–Nrf2 binding to interfere with chondrocyte ferroptosis. International Immunopharmacology. 2024;128:111469. doi:10.1016/j.intimp.2023.111469
BibTeX
@article{Dai2024,
author = {Dai, Zi-Han and Zhou, Chen-Cheng and Yu, Cai-Yu and Qian, Cheng-Jie and Jin, Shu-Qing and Du, Shi-Qi and Lv, Yi-Yun and Jin, Chen and Zheng, Gang and Zhan, Yu},
title = {Gamma-oryzanol alleviates osteoarthritis development by targeting Keap1–Nrf2 binding to interfere with chondrocyte ferroptosis},
journal = {International Immunopharmacology},
year = {2024},
volume = {128},
pages = {111469},
doi = {10.1016/j.intimp.2023.111469}
}
EUVIMED